trending Market Intelligence /marketintelligence/en/news-insights/trending/L0y-Xjp2y1bPNuFDW3aNRg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Ligand Pharmaceuticals closes acquisition of Crystal Bioscience

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Ligand Pharmaceuticals closes acquisition of Crystal Bioscience

Ligand Pharmaceuticals Inc. closed its acquisition of privately held Crystal Bioscience Inc. for an initial consideration of about $25 million in cash.

Crystal is now a wholly owned subsidiary of Ligand.

According to the merger agreement, Crystal shareholders will also receive up to $10.5 million in milestone payments and revenue sharing from existing licensees for a defined period.